Skip to main content

Syndax: Q2 Earnings Snapshot

NEW YORK (AP) — NEW YORK (AP) — Syndax Pharmaceuticals Inc. (SNDX) on Tuesday reported a loss of $49.4 million in its second quarter.

On a per-share basis, the New York-based company said it had a loss of 55 cents.

The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 45 cents per share.

The biopharmaceutical company posted revenue of $72.8 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $81.9 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SNDX at https://www.zacks.com/ap/SNDX

California couple and their surrogate testify in Texas court as dispute over newborn escalates

DALLAS (AP) — A California couple in an escalating fight with their surrogate over a newborn with a life-threatening heart defect told a Texas court Tuesday that the child's condition has worsened and they are anguished by attempts to deny them parental rights because they previously wanted an abortion. “He's our child,” Nausheen Gilkar said, wiping away tears on the witness stand. “She's unstable,” Gilkar said of surrogate McKenna West, who was sitting across from her in the Dallas courtroom. “She's trying to take him from us.” The hearing offered the fullest public airing to date of a deepening and high-profile dispute over surrogacy and abortion that has rushed right-to-life groups and GOP officeholders to the side of West, a nurse who flew from Alaska to have the baby on Aug. 12 in Texas, where most abortions are banned.
Read Next Story